The company leverages these AI platforms to accelerate the identification of promising drug candidates targeting DNA-damage response mechanisms, which are key vulnerabilities in many aggressive cancers. The global DDR therapy market is projected to reach $18 billion annually by 2030, underscoring the potential impact of Rakovina’s innovative approach. The Frankfurt Exchange listing is part of Rakovina's strategy to increase international visibility and establish itself as a leader in oncology drug discovery, while creating long-term value for shareholders and advancing the development of life-saving cancer treatments.
Key takeaways:
- Rakovina Therapeutics Inc. has listed its common shares on the Frankfurt Stock Exchange under the ticker symbol "7J0".
- The listing on the Frankfurt Stock Exchange aims to increase Rakovina's visibility and accessibility to European and global investors.
- Rakovina leverages AI-driven platforms like Deep Docking™ and Variational AI to accelerate the identification of promising drug candidates targeting DNA-damage response mechanisms.
- The global DNA-damage response therapy market is projected to reach $18 billion annually by 2030, highlighting the potential of Rakovina's approach.